ArticleCNS neuroscience & therapeutics2014
Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression.
Article in CNS neuroscience & therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 119 citations in OpenAlex.
- Metrnl Reduces Thrombosis and Acute Myocardial Injury Through Inhibition of Platelet Activation via CD36 Receptor Degradation.Circulation · 2026Article
- Metrnl in mitigating radiation enteritisActa pharmaceutica Sinica. B · 2026Article
- Investigation of testicular METRNL and RARRES2 expression in non-obstructive azoospermia.Journal of applied genetics · 2026Article
- Circulating METRNL, Adipocytokines, and Insulin-Resistance Markers After Repeated Whole-Body Cryotherapy in Women of Different Ages.International journal of molecular sciences · 2026Article
- Metrnl ameliorates ulcerative colitis by inhibiting NLRP3 inflammasome activation via ASC.Scientific reports · 2026Article
- Metrnl in diabetes and its complications: divergent evidence and translational prospects.Journal of translational medicine · 2026Review
- Effects of intracerebroventricular Metrnl administration on the hypothalamic-pituitary-testicular axis in male rats.Molecular biology reports · 2026Article
- Metrnl in health and disease: tissue-specific actions and signaling networks.Apoptosis : an international journal on programmed cell death · 2026Review
- Metrnl and macrophage polarization: role in skeletal muscle homeostasis and therapeutic potential.Frontiers in immunology · 2026Review
- Clinical significance of meteorin-like protein in type 2 diabetes mellitus and its association with carotid plaque complications.Therapeutic advances in endocrinology and metabolism · 2026Article
- Beyond Leptin and Adiponectin: The Diverse Roles of Adipokines in the Myocardial Hypertrophic Process and Heart Failure and Their Potential Contribution in Obesity.International journal of molecular sciences · 2025Review
- Higher serum Metrnl levels are associated with increased vascular calcification in hemodialysis patients.Renal failure · 2025Article
- Construction of a Novel Secreted Protein Database and Identification of a New Adipokine CRELD2.Diabetes & metabolism journal · 2025Article
- The hMetrnl-PLGA-PEG-PLGA Hydrogel Facilitates Skin Wound Healing Through Dual Regulation on eNOS Activity and Stability.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Meteorin-β: A Novel Biomarker and Therapeutic Target on Its Way to the Regulation of Human Diseases.International journal of molecular sciences · 2025Review
- Exploring METRNL as a novel biomarker in sepsis: diagnostic potential and secretion mechanism.Journal of intensive care · 2025Article
- Concentration Dependent Effects of Human Cometin on Spiral Ganglion Neuron Survival and Neurite Outgrowth.Audiology & neuro-otology · 2025Article
- Metrnl and Cardiomyopathies: From Molecular Mechanisms to Therapeutic Insights.Journal of cellular and molecular medicine · 2025Review
- Low serum Metrnl levels are associated with increased risk of sarcopenia in the older adults.European geriatric medicine · 2024Article
- The cytokine Meteorin-like inhibits anti-tumor CD8Immunity · 2024Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAdipose tissue releases adipokines that play important roles in metabolic and cardio-cerebro-vascular homeostasis. This study was to discover novel adipokines using caloric restriction model.
methodsAdipokine candidates were captured by gene array and bioinformatics analysis and verified by preparation of recombinant protein and antibody.
resultsWe established a potential secreted protein database containing 208 genes and identified a novel adipokine, Subfatin, that was the highest expressed in subcutaneous fat of both rodents and humans among 15 detected tissues. The secreted mammalian Subfatin was a glycosylated protein. Subfatin was located diffusely throughout the adipose tissue except lipid droplets, with comparable expression between adipocytes and stromal cells, but much lower expression in macrophages than adipocytes. Subfatin was downregulated in white adipose tissue of caloric restriction rats, whereas dramatically upregulated during white adipocyte differentiation as well as in white adipose tissue of diet-induced obese mice. Subfatin was annotated as Meteorin-like (Metrnl) in public databases, a similar transcript of Meteorin (Metrn, also known as glial cell differentiation regulator). Meteorin displayed a brain-specific expression and was scarce in various adipose tissues, in contrast to the tissue expression patterns of Subfatin.
conclusionsSubfatin is a novel adipokine regulated by adipogenesis and obesity, with tissue distribution different from its homologue Meteorin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.